http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chunxiao Li,Lu Chen,Min Song,Zhirui Fang,Lusha Zhang,Joel Wake Coffie,Liyuan Zhang,Lulu Ma,Qianyi Wang,Wenjie Yang,Leyu Fang,Shaoxia Wang,Xiumei Gao,Hong Wang 대한약학회 2020 Archives of Pharmacal Research Vol.43 No.8
Acute myocardial infarction (AMI) resultsin irreversible cardiac cell damage or death because ofdecreased blood fl ow to the heart. Apoptosis plays an importantrole in the process of tissue damage after myocardialinfarction (MI), which has pathological and therapeuticimplications. Ferulic acid (FA) is a phenolic acid endowedwith strong antioxidative and cytoprotective activities. Thepresent study aimed to investigate whether FA protectscardiomyocytes from apoptosis by regulating autophagy,which is a cellular self-digestion process, and one of thefi rst lines of defense against oxidative stress. Apoptosis wasinduced by TNF-α (10 ng/mL) and cycloheximide (CHX,5 μg/mL) in rat H9c2 cardiomyocytes. FA-inhibited TNF-α/CHX-induced apoptosis was determined by the quantifi cationof TUNEL-positive cells, and the eff ect was associatedwith decreased ROS production and inhibited caspase3activation. FA treatment enhanced autophagy and increasedautophagy-associated protein expression, leading to an inhibitionof mTOR signaling. When co-treated with 3-methyladenine(3-MA), an autophagy inhibitor, the anti-apoptoticeff ect of FA was attenuated. In an in vivo mouse MI model,FA treatment decreased the apoptotic cell number, reducedinfarct size, and improved cardiac performance, as determinedby histological and echocardiographic assessments. Taken collectively, these results suggest that FA could protectcardiomyocytes from apoptosis by enhancing autophagy.
Zhang Yongjia,Cheong Kee Cheok,Wang Qianyi 국립민속박물관 2023 International Journal of Intangible Heritage Vol.18 No.-
The importance of heritage preservation for economic development is now recognised, although not without debate. For cultural assets that have survived threats and perils, the key may lie in adaptation to changed circumstances as much as preservation of traditions. The question then arises whether such adaptation compromises the goal of sustainability. In the present case study of Fishermen’s Dances in Rizhao city, adaptation has resulted in the loss of some long-held traditions. But it has gained a measure of sustainability. Given the strong role of the state, its vision and capability to transform its cultural assets for income-generation activities will be decisive.
Kuikui Jiang,Ruoxi Hong,Wen Xia,Qianyi Lu,Liang Li,Jianhao Huang,Yanxia Shi,Zhongyu Yuan,Qiufan Zheng,Xin An,Cong Xue,Jiajia Huang,Xiwen Bi,Meiting Chen,Jingmin Zhang,Fei Xu,Shusen Wang 대한암학회 2024 Cancer Research and Treatment Vol.56 No.2
Purpose This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice. Materials and Methods This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety. Results A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%). Conclusion Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC.